Intervertebral Disc Fibrosis-Inducing Substance for Spinal Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Intervertebral disc degeneration leads to significant low back pain and spinal instability, with conventional treatments providing limited long-term efficacy due to the disc's weak self-repair and regeneration capabilities.
Innovation Solution
The use of an intervertebral disc fibrosis-inducing substance, comprising bleomycin and/or fibroblasts, which induces high expression of TGF-β, p-Smad2/3, FSP1, and collagen in annulus fibrosus cells, promoting fibrosis and restoring intervertebral disc height and biomechanical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment strategies are used for intervertebral disc degeneration, then symptom relief is achieved, but long-term efficacy is limited due to weak self-repair and regeneration capabilities
Solution Approach 1:
The patent introduces a fibrosis-inducing substance that deliberately promotes fibrotic tissue formation in the intervertebral disc. This converts the potentially harmful fibrotic response into a beneficial therapeutic effect by restoring disc height and stability. The substance triggers a controlled fibrotic reaction that fills the degenerated disc space, maintaining structural integrity and preventing further degeneration, thus converting a pathological process into a therapeutic mechanism.
Solution Approach 2:
The patent changes the biochemical parameters of the intervertebral disc by introducing exogenous fibrosis-inducing substances. These substances alter the disc's composition by promoting collagen deposition and fibrotic tissue formation, thereby changing the physical and mechanical properties of the disc. This parameter change restores the disc's height and biomechanical function, addressing the limitation of conventional treatments that cannot modify the disc's regenerative capacity.
2Reliability
If surgical intervention such as spinal fusion is performed to restore disc height and maintain stability, then severe neurological symptoms are relieved, but biomechanical properties are not restored and adjacent vertebrae may degenerate due to increased mechanical stress
Solution Approach 1:
The patent applies fibrosis-inducing substances locally to the degenerated intervertebral disc rather than performing widespread surgical fusion. This localized treatment promotes fibrotic tissue formation specifically at the treatment site, restoring disc height and stability without affecting adjacent vertebrae. The local application of the substance creates a targeted therapeutic effect that maintains spinal stability while avoiding the propagation of mechanical stress to neighboring segments.
Solution Approach 2:
Instead of using rigid spinal fusion that eliminates motion and transfers stress, the patent utilizes the body's natural fibrotic response as a beneficial mechanism. The induced fibrosis creates a flexible yet stable structure that maintains disc function and distributes mechanical loads more naturally, converting the potentially harmful rigid fixation into a beneficial flexible stabilization that preserves adjacent segment health.
3Ease of operation
If the intervertebral disc is left to rely on its natural self-repair mechanism, then no invasive treatment is required, but the low number of disc cells and lack of nutrient supply prevent effective regeneration
Solution Approach 1:
The patent introduces fibrosis-inducing substances as intermediary agents that mediate between the degenerated disc tissue and the desired regenerative outcome. These substances act as catalysts to stimulate fibrotic tissue formation and cellular activity within the disc, overcoming the natural limitations of low cellularity and poor nutrient supply. The intermediary substance bridges the gap between the disc's limited self-repair capacity and the need for effective regeneration, providing a minimally invasive yet reliable treatment approach.
Data Source
AI summary
A use of an intervertebral disc fibrosis-inducing substance in preparation of medication, where the medication is used for the treatment of degenerative spinal diseases. The inventors of the present disclosure make use of the pro-fibrotic effect of the intervertebral disc fibrosis-inducing substance and the auxiliary effect of the fibroblast to achieve further treatment of intervertebral disc degeneration. The simultaneous administration of the above two drugs can reasonably control the degeneration and achieve the purpose of stepped treatment, thereby having clinical transformation value. In addition, the therapy combining the intervertebral disc fibrosis-inducing substance with the cell in the present disclosure allows the treatment regimen more personalized.